Actinium Pharmaceuticals’ ATNM-400 shows improved survival in prostate cancer

Actinium Pharmaceuticals (ATNM) reported additional preclinical data supporting its ATNM-400 radiotherapy prostate cancer candidate at the 4th Annual Targeted Radiopharmaceuticals Summit in San Diego. ATNM-400 is a first-in-class targeted radiotherapy designed to deliver potent Actinium-225 to prostate cancer cells. The presentation highlighted new PET imaging data showing tumor-specific uptake of ATNM-400, robust tumor control and improved survival outcomes in preclinical studies. ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto and enzalutamide, follow-up continues. ATNM-400 significantly improved survival compared to the approved prostate cancer treatment Pluvicto, the first blockbuster radiotherapy. In combination with enzalutamide, an approved ARPI therapy, ATNM-400 produced enhanced efficacy with 40% of prostate cancer tumor-bearing animals achieving complete cures. ATNM-400 is more efficacious than Pluvicto with potent tumor control. ATNM-400 significantly improved survival compared to Pluvicto with continued follow-up ongoing. ATNM-400 is highly effective in prostate cancer tumors with acquired Pluvicto resistance, halting tumor growth and producing potent tumor cell killing after Pluvicto stops working, highlighting its potential in advanced disease settings that are resistant to standard treatments.